2019 Glaucoma Surgical Device Market Report: A Global Analysis for 2018 to 2024
|発行||Market Scope, LLC||商品コード||644809|
|緑内障手術装置の世界市場 2019 Glaucoma Surgical Device Market Report: A Global Analysis for 2018 to 2024|
|出版日: 2019年08月14日||ページ情報: 英文||
当レポートでは、世界の緑内障手術装置市場について調査し、有病率と予測、外科的介入の役割、現在市販されている製品の市場ダイナミクス、および転帰の改善をもたらすと見られる研究段階にある装置のパイプラインなどの分析を提供しており、製品需要の予測 (数量ベース・金額ベース) 、製品分類別の市場シェア分析、主な戦略的課題に関する議論などをまとめています。
‘The 2019 Glaucoma Surgical Device Market Report’ includes a new section on devices that deliver sustained release of medications and a deep dive analysis of the Alcon CyPass recall that occurred in 2018 and its impact on adoption of minimally invasive glaucoma surgery (MIGS) stents.
‘The 2019 Glaucoma Surgical Device Market Report’ offers a comprehensive analysis of the 2019 global market for glaucoma devices, as well as a discussion of important trends and key factors shaping future success. The report examines the role of surgical intervention, the market dynamics for currently commercialized products, and the pipeline of investigational devices that may offer improved outcomes. Product demand is forecast in units and dollars, and market shares are analyzed by product category.
The report also simplifies the glaucoma surgery categories to four (MIGS, TRABs, tubes, and canal surgery), identifies the MIGS pipeline stents that will drive surgery penetration in each of the stages of glaucoma, and lists 15 early-stage glaucoma surgery device development projects.
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:
Bill Freeman has more than 35 years of experience developing, manufacturing, and marketing cataract surgery products. He has held key executive positions at four firms that produce ophthalmic surgical devices.
Bill's career in ophthalmology began in the 1970s. As president of Cavitron Surgical Systems, he worked with Dr. Charles Kelman in developing and marketing the world's first phacoemulsifier system. While highly controversial in the 1970s, phacoemulsification gradually became the preferred cataract removal technique in the early 1980s. For many years, Cavitron led the cataract instrumentation market.
CooperVision purchased Cavitron in the early 1980s, and Bill joined the company as president of the surgical division. CooperVision expanded its product line to include a wide variety of cataract surgical products-IOLs, viscoelastic solutions, disposable devices, lasers, and custom packs-and became the market leader in many product categories.
In 1989, Alcon acquired CooperVision in an effort to build a strong presence in cataract surgical devices. Bill joined Alcon as general manager of the Irvine Technology Center, where a number of the company's cataract devices, including the Legacy 20000 phacoemulsifier and a broad line of disposable items, were designed and manufactured.
Bill remained with Alcon until 1995. He then joined Mentor Ophthalmics as president of the ophthalmology division. At Mentor, he was responsible for the company's ophthalmic products including IOLs, cautery devices, and surgical instruments.
After leaving Mentor in 1999, Bill joined Market Scope in 2000 and now serves as executive vice president focusing on ophthalmic surgical cataract, retinal and glaucoma devices.